Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (121-130 of 223) with videos related to

Pageof 23
Sort By:
Oncotarget|September 8, 2016
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemiaStefania Fiorcari, Rossana Maffei, Valentina Audrito, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 13, 2017
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic LeukemiaQingsong Yin, Mariela Sivina, Harlan Robins, et al.
Blood|March 26, 2009
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approachMatthias Niedermeier, Bryan T Hennessy, Zachary A Knight, et al.
Blood Cancer Journal|March 14, 2021
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of actionRong Chen, Jennifer Tsai, Philip A Thompson, et al.
Nature Cell Biology|February 21, 2012
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemiaWan Zhang, Dunyaporn Trachootham, Jinyun Liu, et al.
British Journal of Haematology|April 1, 2015
The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experiencePhilip A Thompson, Uri Rozovski, Michael J Keating, et al.
Haematologica|September 28, 2023
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic applicationFiras M Safa, Terri Rasmussen, Lorena Fontan, et al.
Cancer|July 22, 2015
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensPhilip A Thompson, Susan M O'Brien, William G Wierda, et al.
Leukemia|December 22, 2019
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentEkaterina Kim, Elisa Ten Hacken, Mariela Sivina, et al.
Leukemia|October 22, 2020
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemiaMariela Sivina, Lianchun Xiao, Ekaterina Kim, et al.
Pageof 23

Showing results (121-130 of 223) with videos related to

Sort By:
Pageof 23
Oncotarget|September 8, 2016
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemiaStefania Fiorcari, Rossana Maffei, Valentina Audrito, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 13, 2017
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic LeukemiaQingsong Yin, Mariela Sivina, Harlan Robins, et al.
Blood|March 26, 2009
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approachMatthias Niedermeier, Bryan T Hennessy, Zachary A Knight, et al.
Blood Cancer Journal|March 14, 2021
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of actionRong Chen, Jennifer Tsai, Philip A Thompson, et al.
Nature Cell Biology|February 21, 2012
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemiaWan Zhang, Dunyaporn Trachootham, Jinyun Liu, et al.
British Journal of Haematology|April 1, 2015
The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experiencePhilip A Thompson, Uri Rozovski, Michael J Keating, et al.
Haematologica|September 28, 2023
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic applicationFiras M Safa, Terri Rasmussen, Lorena Fontan, et al.
Cancer|July 22, 2015
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensPhilip A Thompson, Susan M O'Brien, William G Wierda, et al.
Leukemia|December 22, 2019
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentEkaterina Kim, Elisa Ten Hacken, Mariela Sivina, et al.
Leukemia|October 22, 2020
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemiaMariela Sivina, Lianchun Xiao, Ekaterina Kim, et al.
Pageof 23